市場調查報告書

局部麻醉劑的全球市場:麻醉劑的種類及各用途分析 - 成長,趨勢及預測(2018年∼2023年)

Local Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 391453
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
局部麻醉劑的全球市場:麻醉劑的種類及各用途分析 - 成長,趨勢及預測(2018年∼2023年) Local Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球局部麻醉劑市場,估計2017年達到60億2000萬美元。全球局部麻醉劑市場,預計從2018年到2023年的預測期間內以3.9%的年複合成長率成長。北美,由於PROPOFOL的需求增加,支配著市場。

本報告提供全球局部麻醉劑市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭優勢

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 外科醫生的增加
    • 麻醉劑的新核准
    • 美容整形手術的增加
  • 市場阻礙因素
    • 麻醉劑的副作用的危險性
    • 各政府法規上的問題
  • 機會
  • 主要課題
    • 市場區隔
    • 其他局部麻醉

第7章 各地區市場區隔

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲地區
  • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作及合作
  • 新產品的銷售

第9章 企業簡介

  • BAXTER
  • MYLAN
  • ABBOTT
  • ASTRAZENECA
  • TEVA PHARMACEUTICALS
  • PFIZER
  • FRESENIUS SE & CO
  • HIKMA PHARMACEUTICALS PLC

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 46482

Anesthesia is one of the most essential components for any surgical procedure. It induces temporary unconsciousness and loss of protective reflexes. According to the Centers for Disease Control and Prevention (CDC), more than 51 million inpatient surgeries and 53 million outpatient surgeries were performed in the United States in 2017, with the cardiology, surgical, and obstetrical procedures being the most common ones. In Europe, a greater number of surgeries are being performed for cases of cataract, tonsillectomy, colonoscopy, caesarean sections, and hip replacements. In addition, a number of procedures, such as cochlear implantation, laparoscopic colectomy, laparoscopic hysterectomy, secondary hip replacement, and knee replacement, have become more frequent in the recent years. Hence, the overall increase in the number of surgeries performed has a strong impact on the anesthetic drug market, as these drugs are used in all surgical procedures to reduce pain during surgery.

Key Market Trends

Bupivacaine is Expected to Register a Significant Growth in the Forecast Years

Based on drug type, it is segmented into bupivacaine, lidocaine, benzocaine, ropivacaine, prilocaine, chloroprocaine, and other local anesthetics. Bupivacaine is a local anesthetic drug that has been used in various surgical procedures. This is helpful in blocking the nerve impulses that send pain signals to the brain. As per the Royal College of Surgeons, in England (U.K), there were around 4.7 million surgical admissions in 2013/14. There has been a 27% increase in the number of admissions for surgical procedures between 2003-2004 and 2013-14. The most common surgical procedures are hernia repairs, hip replacement, knee replacement, gall bladder removal, and tonsillectomies. Bupivacaine is widely used as local anesthesia, due to its efficacy in numbing certain organ. Hence, the rising number of surgeries leads to high demand for local anesthesia drugs and is expected to propel the growth of the market.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the local anesthesia drugs market and is expected to continue its stronghold for a few more years. The US anesthesia market is the largest regional market in the world. The market is mainly driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions and advancements in anesthesia technologies. Due to the rising scope of local anesthesia in the market, key players are taking efforts to come up with novel and innovative drugs, thus fueling market growth.

Competitive Landscape

The Local Anesthesia Drugs market is competitive and many of the global players are into the market. Companies are focusing on major collaborations, mergers, and acquisitions in order to enhance their market share. Market players are also focusing on R&D to improve product quality and minimize manufacturing costs, developing novel products to improve patient compliance and safety. Some of the key developments in the market are, in August 2017: Akovaz (Ephedrine Sulfate) injection manufactured by Sandoz Inc. for the treatment of clinically important hypotension got approval of FDA and in July: 2017: Septocaine a local, infiltrative or conductive anesthesia, which is used in dental procedures developed by Hansamed Inc., got FDA approval.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Surgeries
    • 4.2.2 New Approval of Anesthetic Drugs
    • 4.2.3 Growing Use of Local Anesthetic in Post-operative Pain
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anesthetic Drugs
    • 4.3.2 Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 Bupivacaine
    • 5.1.2 Lidocaine
    • 5.1.3 Benzocaine
    • 5.1.4 Ropivacaine
    • 5.1.5 Prilocaine
    • 5.1.6 Chloroprocaine
    • 5.1.7 Others
  • 5.2 By Mode of Administration
    • 5.2.1 Injectable
    • 5.2.2 Surface Anesthetic
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Fresenius SE & Co. KGaA
    • 6.1.3 Glenmark Pharmaceutical Inc.
    • 6.1.4 Mylan N.V.
    • 6.1.5 Pacira Pharmaceuticals, Inc.
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Septodont
    • 6.1.8 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS